← Leaderboards
David A. Nathanson
University Of California Los Angeles
$10,691,258
Attributed
$17,228,738
Total exposure
11
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,228,738 · 11
By mechanism
R01$12,648,590 · 6
P50$3,257,261 · 3
T32$899,387 · 1
R21$423,500 · 1
Top collaborators
- Benjamin M. Ellingson7 shared
- Scott Dixon6 shared
- Steven J Bensinger5 shared
- Thomas G Graeber5 shared
- Timothy Cloughesy4 shared
- Gay Miriam Crooks2 shared
- Stephanie Kristin Seidlits2 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Benjamin M. Ellingson$5,183,626
- Scott Dixon$7,011,429
- Steven J Bensinger$10,918,290
- Sanjiv S Gambhir$44,452,033
- Sherin U. Devaskar$31,339,941
Others in their field
Top investigators on “Glioblastoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$50,454,235
- John H Sampson · Duke University$34,869,540
- Walter John Curran · Thomas Jefferson University$27,327,059
- Jann N Sarkaria · Mayo Clinic Coll Of Medicine, Rochester$23,947,143
- Jeremy N Rich · University Of Pittsburgh At Pittsburgh$21,935,828
- Maciej S Lesniak · Northwestern University$18,837,339
Research focus
GlioblastomaTumorEpidermal Growth Factor ReceptorMalignant NeoplasmsMolecularIn VivoBrainTargeted TreatmentPathway InteractionsExhibitsOncogenicResponseMeasurementMetabolicXenograft ProcedureRecurrenceNeoplastic CellNovel TherapeuticsCharacteristicsGliomaMetabolismCellsMalignant GliomaClinical Trials
Grant awards (37)
Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastoma$607,842
R01 · FY2025 · CA
Investigating non-apoptotic cell death in glioblastoma$595,047
R01 · FY2025 · NS · contact PI
Quantitative molecular MR-PET imaging of glycolysis in glioblastoma$594,570
R01 · FY2025 · CA
CDKN2A couples lipid metabolism to ferroptosis in glioblastoma$464,096
R01 · FY2025 · NS · contact PI
Tumor Cell Biology Training Program$412,722
T32 · FY2025 · CA
Project 2: Overcoming drug-induced resistance to intrinsic apoptosis in glioblastoma$402,689
P50 · FY2025 · CA · contact PI
Project 2: Overcoming drug-induced resistance to intrinsic apoptosis in glioblastoma$8,612
P50 · FY2025 · CA · contact PI
Quantitative molecular MR-PET imaging of glycolysis in glioblastoma$588,416
R01 · FY2024 · CA
Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastoma$587,142
R01 · FY2024 · CA
CDKN2A couples lipid metabolism to ferroptosis in glioblastoma$501,221
R01 · FY2024 · NS · contact PI
Tumor Cell Biology Training Program$486,665
T32 · FY2024 · CA
Project 2: Overcoming drug-induced resistance to intrinsic apoptosis in glioblastoma$403,620
P50 · FY2024 · CA · contact PI
Quantitative molecular MR-PET imaging of glycolysis in glioblastoma$619,045
R01 · FY2023 · CA
Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastoma$605,684
R01 · FY2023 · CA
CDKN2A couples lipid metabolism to ferroptosis in glioblastoma$517,754
R01 · FY2023 · NS · contact PI
Project 2: Overcoming drug-induced resistance to intrinsic apoptosis in glioblastoma$369,086
P50 · FY2023 · CA · contact PI
Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastoma$623,037
R01 · FY2022 · CA
Mammalian models for integrated metabolic and molecular profiling of malignant glioma$543,028
R01 · FY2022 · CA · contact PI
CDKN2A couples lipid metabolism to ferroptosis in glioblastoma$518,756
R01 · FY2022 · NS · contact PI
Project 2: Overcoming drug-induced resistance to intrinsic apoptosis in glioblastoma$363,074
P50 · FY2022 · CA · contact PI
Mammalian models for integrated metabolic and molecular profiling of malignant glioma$554,109
R01 · FY2021 · CA · contact PI
CDKN2A couples lipid metabolism to ferroptosis in glioblastoma$533,806
R01 · FY2021 · NS · contact PI
Targeting metabolic vulnerabilities in glioblastoma$490,971
R01 · FY2021 · CA · contact PI
Project 2: Targeting metabolic vulnerabilities in glioblastoma$334,315
P50 · FY2021 · CA · contact PI
Mammalian models for integrated metabolic and molecular profiling of malignant glioma$554,109
R01 · FY2020 · CA · contact PI
Targeting metabolic vulnerabilities in glioblastoma$490,971
R01 · FY2020 · CA · contact PI
Project 2: Targeting metabolic vulnerabilities in glioblastoma$341,625
P50 · FY2020 · CA · contact PI
Targeting metabolic vulnerabilities in glioblastoma$555,887
R01 · FY2019 · CA · contact PI
Mammalian models for integrated metabolic and molecular profiling of malignant glioma$537,485
R01 · FY2019 · CA · contact PI
Project 2: Targeting metabolic vulnerabilities in glioblastoma$334,315
P50 · FY2019 · CA · contact PI
Mammalian models for integrated metabolic and molecular profiling of malignant glioma$553,813
R01 · FY2018 · CA · contact PI
Targeting metabolic vulnerabilities in glioblastoma$500,340
R01 · FY2018 · CA · contact PI
Project 2: Targeting metabolic vulnerabilities in glioblastoma$359,605
P50 · FY2018 · CA · contact PI
Targeting metabolic vulnerabilities in glioblastoma$511,461
R01 · FY2017 · CA · contact PI
Project 2: Targeting metabolic vulnerabilities in glioblastoma$340,320
P50 · FY2017 · CA · contact PI
Engineered microenvironments as biomimetic culture platforms for studying the role of brain extracellular matrix in acquisition of resistance to EGFR inhibition across multiple biological scales$192,500
R21 · FY2016 · NS
Engineered microenvironments as biomimetic culture platforms for studying the role of brain extracellular matrix in acquisition of resistance to EGFR inhibition across multiple biological scales$231,000
R21 · FY2015 · NS